Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Mr. Edward  Chiang

Senior Vice President of Clinical & Technical Operations

Mr. Thomas W. Hare

Senior Vice President of Clinical Management

Dr. Stephen  Dodge M.B.A., Pharm.D.

Senior Vice President of Global Medical Affairs

Ms. Tina E. Ventura

Chief Investor Relations Officer

Mr. Alex G. Howarth

Executive Officer

Mr. Clint  Wallace

Chief Human Resources Officer

Mr. William J. Sibold

Chief Executive Officer, President & Director

Dr. Robert E. Waltermire Ph.D.

Chief Pharmaceutical Development Officer

Mr. Ronald  Filippo

Chief Information Officer

Dr. Rebecca A. Taub M.D.

Founder, Chief Medical Officer, President of Research & Development and Director

Biotechnologie

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. Structure de gestion

Informations sur la direction